Taysha Gene Therapies Return on Investment 2020-2024 | TSHA
Current and historical return on investment (ROI) values for Taysha Gene Therapies (TSHA) over the last 10 years.
| Taysha Gene Therapies ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2024-09-30 |
$-0.09B |
$0.13B |
-71.31% |
| 2024-06-30 |
$-0.08B |
$0.15B |
-89.28% |
| 2024-03-31 |
$-0.08B |
$0.09B |
-158.79% |
| 2023-12-31 |
$-0.07B |
$0.12B |
-225.00% |
| 2023-09-30 |
$-0.11B |
$-0.01B |
-861.54% |
| 2023-06-30 |
$-0.12B |
$0.00B |
-432.14% |
| 2023-03-31 |
$-0.13B |
$0.02B |
-289.50% |
| 2022-12-31 |
$-0.16B |
$0.04B |
-266.67% |
| 2022-09-30 |
$-0.16B |
$0.05B |
-185.88% |
| 2022-06-30 |
$-0.18B |
$0.07B |
-160.35% |
| 2022-03-31 |
$-0.19B |
$0.09B |
-197.43% |
| 2021-12-31 |
$-0.17B |
$0.13B |
-231.23% |
| 2021-09-30 |
$-0.14B |
$0.17B |
-338.10% |
| 2021-06-30 |
$-0.11B |
|
inf% |
| 2021-03-31 |
$-0.07B |
|
inf% |
| 2020-12-31 |
$-0.04B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.434B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
